AI assistant
ALCIDION GROUP LIMITED — Director's Dealing 2018
Apr 30, 2018
64360_rns_2018-04-30_b2f55238-eda5-4011-b8ac-3272d99656e4.pdf
Director's Dealing
Open in viewerOpens in your device viewer
==> picture [123 x 36] intentionally omitted <==
1 May 2018
Australian Securities Exchange 20 Bridge Street, Sydney NSW 2000
Alcidion Appendix 3Y Notifications
Adelaide, South Australia, 1 May 2018 - Alcidion Group Limited (ASX: ALC ), has today lodged Appendix 3Y notifications relating to the purchase of shares by the following directors or their associates: Ray Blight (3.02 million shares), Rebecca Wilson (570,000 shares) and Geoff Rohrsheim (1 million shares).
The directors were previously restricted from purchasing shares due to a trading blackout in place whilst the acquisition of MKM Health and Patientrack, announced to the market last week, was being negotiated.
Ray Blight, CEO of Alcidion Group said, “I am pleased to increase my position as a shareholder, and to welcome two of our Directors as fellow shareholders of the company. It has been their intention to buy shares and, now that trading restrictions have been lifted, they have promptly followed through with this. The MKM acquisition is transformative and we look forward to presenting to investors at our roadshow underway this week.”
### ENDS ###
For further information, please contact: Ray Blight, Chief Executive Officer Kyahn Williamson, WEBuchan Ph: +61 (08) 8208 4600 Ph: 0401018828 Alcidion Group Limited [email protected] [email protected]
About Alcidion
Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.
Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.
www.alcidion.com
© Alcidion Group Limited 2018. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.
==> picture [595 x 9] intentionally omitted <==
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644
Appendix 3Y Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | ALCIDION GROUP LIMITED |
|---|---|
| ABN | 77 143 142 410 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | RAYMOND HOWARD | BLIGHT |
|---|---|---|
| Date of last notice | 23/12/2016 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | DIRECT & INDIRECT |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
SHARES HELD BY SPOUSE (ROBYN GAILE MORRIS) |
| Date of change | 24-27 April 2018 |
| No. of securities held prior to change | 97,051,004 |
| Class | FULLY PAID ORDINARY SHARES |
| Number acquired | 3,020,000 |
| Number disposed | NIL |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
$129,172 |
| No. of securities held after change | 100,071,004 FULLY PAID ORDINARY SHARES - |
- See chapter 19 for defined terms.
01/01/2011
Appendix 3Y Page 1
Appendix 3Y Change of Director’s Interest Notice
Nature of change ON-MARKET TRADES Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
| Interest after change | N/A |
Part 3 –[+] Closed period
| Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required? |
NO |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If prior written clearance was provided, on what date was this provided? |
N/A |
- See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
==> picture [123 x 37] intentionally omitted <==
1 May 2018
Australian Securities Exchange 20 Bridge Street Sydney NSW 2000
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | ALCIDION GROUP LIMITED |
|---|---|
| ABN | 77 143 142 410 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | GEOFF ROHRSHEIM |
|---|---|
| Date of last notice | 31/07/2017 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | INDIRECT |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
G R ROHRSHEIM NOMINEES PTY LTD ATF ROHRSHEIM SUPER FUND |
| Date of change | 26 APRIL 2018 |
| No. of securities held prior to change | NIL |
| Class | FULLY PAID ORDINARY SHARES |
| Number acquired | 1,000,000 FULLY PAID ORDINARY SHARES |
| Number disposed | - |
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644
==> picture [123 x 37] intentionally omitted <==
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
$40,621.15 PAID FOR FULLY PAID ORDINARY SHARES |
|---|---|
| No. of securities held after change | 1,000,000 FULLY PAID ORDINARY SHARES |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
ON-MARKET TRADE |
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644
==> picture [123 x 37] intentionally omitted <==
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
|---|---|
| Interest after change | N/A |
Part 3 –[+] Closed period
| Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required? |
No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If prior written clearance was provided, on what date was this provided? |
N/A |
### ENDS ###
For further information, please contact:
Duncan Craig
Chief Financial Officer and Company Secretary Ph: +61 (08) 8208 4600 Alcidion Corporation [email protected]
About Alcidion
Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.
Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.
www.alcidion.com
© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644
==> picture [123 x 37] intentionally omitted <==
1 May 2018
Australian Securities Exchange 20 Bridge Street Sydney NSW 2000
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
| Name of entity | ALCIDION GROUP LIMITED |
|---|---|
| ABN | 77 143 142 410 |
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | REBECCA WILSON |
|---|---|
| Date of last notice | 31/07/2017 |
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Direct or indirect interest | DIRECT |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. |
|
| Date of change | 27APRIL 2018 |
| No. of securities held prior to change | NIL |
| Class | FULLY PAID ORDINARY SHARES |
| Number acquired | 570,000 FULLY PAID ORDINARY SHARES |
| Number disposed | - |
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644
==> picture [123 x 37] intentionally omitted <==
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation |
$25,080 PAID FOR FULLY PAID ORDINARY SHARES |
|---|---|
| No. of securities held after change | 570,000 FULLY PAID ORDINARY SHARES |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back |
ON-MARKET TRADES |
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract | N/A |
|---|---|
| Nature of interest | N/A |
| Name of registered holder (if issued securities) |
N/A |
| Date of change | N/A |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed |
N/A |
| Interest acquired | N/A |
| Interest disposed | N/A |
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644
==> picture [123 x 37] intentionally omitted <==
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation |
N/A |
|---|---|
| Interest after change | N/A |
Part 3 –[+] Closed period
| Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required? |
No |
|---|---|
| If so, was prior written clearance provided to allow the trade to proceed during this period? |
N/A |
| If prior written clearance was provided, on what date was this provided? |
N/A |
### ENDS ###
For further information, please contact:
Duncan Craig
Chief Financial Officer and Company Secretary Ph: +61 (08) 8208 4600 Alcidion Corporation [email protected]
About Alcidion
Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.
Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.
www.alcidion.com
© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies
[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia | +61 1800 767 873 | � +61 8 8271 2644